Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASH 2015 - Multiple Myeloma
Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma (CHAMPION-1)
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Safety of Pomalidomide/Low-Dose Dexamethasone Treatment in Renally Impaired Patients with Relapsed or Refractory Multiple Myeloma
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Pomalidomide/Dexamethasone/Ixazomib versus Pomalidomide/Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma: Results of Phase 1/2 Alliance A061202
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Novel Kinesin Spindle Protein Inhibitor Filanesib Plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Ibrutinib plus Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: Results of an Ongoing Phase 1/2b Study (PCYC-1119)
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Pembrolizumab plus Lenalidomide/Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (KEYNOTE-023)
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Pembrolizumab, Pomalidomide, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase 2 Study
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Daratumumab plus Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Results of the GEN503 Study
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Elotuzumab plus Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 2 Study (CA204-009T)
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Dose-Finding Phase 2 Trial of Single-Agent Isatuximab in Relapsed/Refractory Multiple Myeloma
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma